Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial

赛马鲁肽 医学 磷酸西他列汀 耐受性 中止 临床终点 杜拉鲁肽 内科学 艾塞那肽 2型糖尿病 随机对照试验 利拉鲁肽 糖尿病 不利影响 磷酸西他列汀 内分泌学
作者
Thomas R. Pieber,Bruce W. Bode,Ann C. Mertens,Young Min Cho,Erik Christiansen,CHRISTIN L. HERTZ,Signe Olrik Rytter Wallenstein,John B. Buse,Serkan Akın,Nesim Aladağ,Ahmed A. Arif,Louis J. Aronne,S Aronoff,Hayriye Esra Ataoğlu,Sei Hyun Baik,Harold Bays,Patricia Beckett,Dilek Berker,Stefan Bilz,Bruce W. Bode
出处
期刊:The Lancet Diabetes & Endocrinology [Elsevier BV]
卷期号:7 (7): 528-539 被引量:209
标识
DOI:10.1016/s2213-8587(19)30194-9
摘要

Oral semaglutide is the first oral formulation of a glucagon-like peptide-1 (GLP-1) receptor agonist developed for the treatment of type 2 diabetes. We aimed to compare the efficacy and safety of flexible dose adjustments of oral semaglutide with sitagliptin 100 mg.In this 52-week, multicentre, randomised, open-label, phase 3a trial, we recruited patients with type 2 diabetes from 81 sites in ten countries. Patients were eligible if they were aged 18 years or older (19 years or older in South Korea), had type 2 diabetes (diagnosed ≥90 days before screening), HbA1c of 7·5-9·5% (58-80 mmol/mol), and were inadequately controlled on stable daily doses of one or two oral glucose-lowering drugs (for 90 days or more before screening). Participants were randomly assigned (1:1) by use of an interactive web-response system, stratified by background glucose-lowering medication at screening, to oral semaglutide with flexible dose adjustments to 3, 7, or 14 mg once daily or sitagliptin 100 mg once daily. To approximate treatment individualisation in clinical practice, oral semaglutide dose could be adjusted on the basis of prespecified HbA1c and tolerability criteria. Two efficacy-related estimands were prespecified: treatment policy (regardless of treatment discontinuation or use of rescue medication) and trial product (on treatment and without use of rescue medication) for participants randomly assigned to treatment. The primary endpoint was achievement of HbA1c of less than 7% (53 mmol/mol) at week 52 and the confirmatory secondary efficacy endpoint was change in bodyweight from baseline to week 52. Safety was assessed in all participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov, number NCT02849080, and European Clinical Trials Database, EudraCT number 2015-005593-38, and an open-label extension is ongoing.Between Sept 20, 2016, and Feb 7, 2017, of 804 patients assessed for eligibility, 504 were eligible and randomly assigned to oral semaglutide (n=253) or sitagliptin (n=251). Most participants were male (285 [57%] of 504) with a mean age of 57·4 years (SD 9·9). All participants were given at least one dose of their allocated study drug except for one participant in the sitagliptin group. From a mean baseline HbA1c of 8·3% (SD 0·6%; 67 mmol/mol [SD 6·4]), a greater proportion of participants achieved an HbA1c of less than 7% with oral semaglutide than did with sitagliptin (treatment policy estimand: 58% [134 of 230] vs 25% [60 of 238]; and trial product estimand: 63% [123 of 196] vs 28% [52 of 184]). The odds of achieving an HbA1c of less than 7% was significantly better with oral semaglutide than sitagliptin (treatment policy estimand: odds ratio [OR] 4·40, 95% CI 2·89-6·70, p<0·0001; and trial product estimand: 5·54, 3·54-8·68, p<0·0001). The odds of decreasing mean bodyweight from baseline to week 52 were higher with oral semaglutide than with sitagliptin (estimated mean change in bodyweight, treatment policy estimand: -2·6 kg [SE 0·3] vs -0·7 kg [SE 0·2], estimated treatment difference [ETD] -1·9 kg, 95% CI -2·6 to -1·2; p<0·0001; and trial product estimand: -2·9 kg [SE 0·3] vs -0·8 kg [SE 0·3], ETD -2·2 kg, -2·9 to -1·5; p<0·0001). Adverse events occurred in 197 (78%) of 253 participants in the oral semaglutide group versus 172 (69%) of 250 in the sitagliptin group, and nausea was the most common adverse event with oral semaglutide (53 [21%]). Two deaths occurred in the sitagliptin group during the trial.Oral semaglutide, with flexible dose adjustment, based on efficacy and tolerability, provided superior glycaemic control and weight loss compared with sitagliptin, and with a safety profile consistent with subcutaneous GLP-1 receptor agonists.Novo Nordisk A/S.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
2秒前
3秒前
3秒前
路漫漫123完成签到,获得积分10
4秒前
英俊的铭应助温暖的以旋采纳,获得10
4秒前
量子星尘发布了新的文献求助10
5秒前
大白发布了新的文献求助20
5秒前
6秒前
ZZ发布了新的文献求助10
6秒前
马马发布了新的文献求助10
6秒前
Ss发布了新的文献求助30
6秒前
上官若男应助Nnn采纳,获得100
7秒前
8秒前
木火灰完成签到,获得积分10
8秒前
8秒前
丸丸发布了新的文献求助10
9秒前
10秒前
Ayao完成签到,获得积分10
11秒前
slx0410完成签到,获得积分10
11秒前
小紫完成签到,获得积分10
11秒前
12秒前
今后应助小小橙采纳,获得10
12秒前
SciGPT应助科研通管家采纳,获得10
12秒前
SYLH应助科研通管家采纳,获得10
12秒前
Owen应助科研通管家采纳,获得10
12秒前
SYLH应助科研通管家采纳,获得30
12秒前
在水一方应助马马采纳,获得10
12秒前
FashionBoy应助科研通管家采纳,获得10
13秒前
烟花应助末末采纳,获得10
13秒前
领导范儿应助科研通管家采纳,获得10
13秒前
13秒前
SYLH应助科研通管家采纳,获得30
13秒前
小二郎应助科研通管家采纳,获得10
13秒前
CodeCraft应助科研通管家采纳,获得10
13秒前
FashionBoy应助科研通管家采纳,获得10
13秒前
静静应助科研通管家采纳,获得10
13秒前
13秒前
orixero应助科研通管家采纳,获得10
13秒前
彭于晏应助科研通管家采纳,获得10
13秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975816
求助须知:如何正确求助?哪些是违规求助? 3520159
关于积分的说明 11201128
捐赠科研通 3256541
什么是DOI,文献DOI怎么找? 1798347
邀请新用户注册赠送积分活动 877539
科研通“疑难数据库(出版商)”最低求助积分说明 806426